New data from the NOVA trial showed differences in the number of T2 lesions in patients with relapsing-remitting multiple sclerosis at 72 weeks of treatment with natalizumab (Tysabri; Biogen), though seemingly driven by data from only 2 participants with extreme new or newly enlarging T2 hyperintense lesion numbers.
Valproic acid, which had been associated with a variety of major and minor malformations in pregnancy, remained barely unchanged in terms of use, dropping slightly from 12.4% to 10.1% over the 5-year period.
The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discussed updates in ALS research along with the need in future studies following AMX005’s (Relyvrio; Amylyx Pharmaceuticals) recent FDA approval. [WATCH TIME: 4 minutes]
A study using patient data from John Hopkins showed that rituximab treatment was associated with reduced annualized relapse rates in AQP4-IgG seropositive NMOSD and MOGAD.
The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology discussed current knowns and unknowns about the pathology of Alzheimer disease. [WATCH TIME: 4 minutes]
Joe Kardine, MS, OTR, CBIS, the clinical program manager at the Jefferson Center for Neurorestoration, discussed the influx of new neurorestorative technology and the future of treating patients with functional loss.
In a cohort of nearly 600,000 individuals, the combination of dementia diagnosis and presence of psychiatric comorbidity significantly increased the risk of suicide.
The division chief of stroke and vascular neurology at Duke Health provided insight on the nuances of poststroke neuromuscular symptoms and how they differ from other typically managed impairments. [WATCH TIME: 5 minutes]
The TRACK-TBI cohort study revealed that patients with traumatic brain injury and a GCS score of 3 to 12 had a significant increase in the accuracy of prognostic accuracy of IMPACT models.
The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses Amylyx’s therapy that was recently approved by the FDA, and what it means for the ALS community and the global healthcare industry. [WATCH TIME: 5 minutes]
The NDA for the Supernus therapy, supported by data from the phase 3 TOLEDO study in patients with Parkinson disease, will require additional information and 6 months of further review. No additional efficacy or safety studies are required.
Here's some of what is coming soon to NeurologyLive® this week.
Enrollment for the phase 1/2 study will be partially stopped; however, all participants included in the trial, whether on AOC 1001 or placebo, are eligible to continue their current dosing regimen.
The clinical program manager at the Jefferson Center for Neurorestoration provided commentary on the state of neurorestoration and constant transformation of the space. [WATCH TIME: 3 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is insomnia.
Data from a MSbase registry on patients with multiple sclerosis show in its findings that the incorporation of the Multiple Sclerosis Severity Score improved the prediction accuracy of relapses in MS.
Findings from a study on Parkinson disease revealed that combining blood biomarkers in addition with clinical measures with prognostics modelling are associated with a more vital prediction in disease progression.
Using magnetic resonance spectroscopy, investigators observed significantly different levels of total NAA across MS and NMOSD subtypes, and a negative correlation between total NAA and disability score.
Neurology News Network for the week ending October 8, 2022. [WATCH TIME: 3 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 7, 2022.
When hydromethylthionine mesylate was compared with publicly available placebo decline data, the treatment effects of cognitive and functional decline are about 3-fold larger over 18 months.
The neurologist at the University of California, San Francisco offered an overview of the State of the Science Summit that was held on September 28, 2022, featuring a panel of expert clinicians. [WATCH TIME: 7 minutes]
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Yuri Maricich, MD, MBA. [LISTEN TIME: 30 minutes]
Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
Expert clinicians offer their perspectives on developmental milestones for children, the NMSOD patient perspective, effective treatments for insomnia, ALS, diabetic and inflammatory neuropathies, and lecanemab in early Alzheimer disease.
Recent findings from a network meta-analysis suggest that high flow oxygen is more efficacious when compared with low flow oxygen for headache relief.
A narrative review revealed that cluster headache trials have been limited thus far, and that future trials should include novel outcome measures and adjusted end point timing.
The professor of neurology at Johns Hopkins Medicine provided an in-depth look at the 2022 RNDS and the unique design it offers patients with rare neuroimmune disorders. [WATCH TIME: 3 minutes]
The RNDS, created to bring together those with rare neuroimmune disorders and clinical community together, is a 3-day hybrid educational event held October 7-9 in Los Angeles, California
In 2 phase 3 randomized placebo-controlled trials, findings showed that although crenezumab was well tolerated, it did not reduce clinical decline in participants with early Alzheimer disease.
